Drug Profile
Research programme: brain development disorder therapeutics - Seaside Therapeutics
Alternative Names: mGluR5 antagonists - Seaside; muscarinic M1 receptor antagonists - Seaside; STX 110Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Seaside Therapeutics
- Class
- Mechanism of Action Metabotropic glutamate receptor 5 antagonists; Muscarinic M1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autistic disorder; Fragile X syndrome
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autistic-disorder in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Fragile-X-syndrome in USA
- 31 Dec 2011 Preclinical development is ongoing for Fragile X syndrome and Autism in the US